VRNA Price Prediction Next Week
Analysis and Insights
Fundamental Analysis:
Verona Pharma (VRNA) has shown strong positive momentum recently, driven by analyst upgrades and promising product performance. Multiple analysts have raised their price targets for VRNA, reflecting confidence in the company's growth prospects. Truist raised its target from $57 to $76, while Roth MKM increased it from $68 to $83, signaling a bullish outlook on the stock.
Technical Analysis:
The stock is currently trading at $61.04, with key technical indicators suggesting a bullish trend. The RSI (14) is at 55.25, indicating the stock is not overbought, and the MACD is positive at 2.85, signaling upward momentum. The Stochastic Oscillator shows a bullish crossover with K at 48.77 and D at 60.93, further supporting the positive outlook.
Event Impact Assessment:
A meeting with Truist on March 10 could act as a catalyst for the stock. Positive news from this meeting may drive further upward momentum, building on the already strong analyst sentiment.
Price Target and Recommendation:
Based on the positive analyst sentiment, strong technical indicators, and upcoming catalysts, the stock is expected to rise to $66.25 in the next trading week. This represents a bullish outlook, making it a good time to buy.
Prediction: Buy VRNA with a target price of $66.25.
VRNA Similar Chart Price Prediction
The price of VRNA is predicted to go up 8.59%, based on the high correlation periods with GATX. The similarity of these two price pattern on the periods is 97.5%.
VRNA
GATX
Up: 8.59%Similarity: 97.5%
VRNA Revenue Forecast
VRNA EPS Forecast
VRNA FAQs
What is VRNA revenue forecast for next quarter？
What is VRNA eps forecast for next quarter？
VRNA Analyst's Forecast
Edward Nash
Canaccord Genuity
Strong Buy
2025-02-12
Price Target
$44 → $72
Upside
+14.83%
Canaccord raised the firm's price target on Verona Pharma to $72 from $44 and keeps a Buy rating on the shares. The firm believes the strong launch of Ohtuvayre to-date signals a strong future in the treatment of COPD. Given that Ohtuvayre is the first new mechanism for COPD to be approved in decades with a dual mechanism focused on both inflammation and bronchodilation, Canaccord believes physicians are viewing the drug as a game changer.
Boobalan Pachaiyappan
Roth MKM
Strong Buy
2025-01-10
Price Target
$68
Upside
+50.44%
Tiago Fauth
Wells Fargo
Buy
2025-01-08
Price Target
$64 → $74
Upside
+60.17%
